Adaptive Biotechnologies Corporation (ADPT) Stock

About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation (ADPT) stock trades at $25.51 with a market capitalization of $4.07B. The stock is valued at a negative price-to-earnings (P/E) ratio of -71.77, reflecting a net loss over the last twelve months, price-to-book of 32.27, price-to-sales of 15.19. Over the past 52 weeks the stock has ranged between $12.00 and $30.30, and currently trades 15.8% below its 52-week high.

On profitability, Adaptive Biotechnologies Corporation generates a return on equity (ROE) of -32.64% (negative, reflecting a net loss), return on capital employed of -6.77%, an operating margin of -15.82%, a net profit margin of -20.73%.

Adaptive Biotechnologies Corporation by the numbers, 2017–2025

Between 2017 and 2025 Adaptive Biotechnologies Corporation reported revenue of $38.0M rising to $277.0M, a change of +628.9% across 9 years. Compounded, revenue has grown 23.1% a year over five years, 14.4% over three, 54.8% over the last twelve months. Net profit fell to $-59.0M.

Operating margin went from -115.7% in 2017 to -20.6% in 2025, a gain of 95.1 percentage points. The most recent net margin is -20.73%. On a trailing twelve-month basis to Jun '26, revenue is $309.0M and net profit $-64.0M.

Borrowings fell from $562.0M to $281.0M, cash from operations was $-46.0M in the latest year, positive in 1 of the last 9.

Return on equity has averaged -51.1% over five years, and was -26.9% in the most recent year.

The share price itself has compounded at -14.2% a year over five years, 28.1% over three, 71.1% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Adaptive Biotechnologies Corporation (ADPT) — frequently asked questions